Related Experiment Video
Updated: Jun 20, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Potential vascular actions of 2-methoxyestradiol
Raghvendra K Dubey1, Edwin K Jackson
1Clinic for Reproductive Endocrinology, Department of Obstetrics and Gynecology, Zurich Center for Integrative Human Physiology, University Hospital Zurich, Frauenklinikstrasse, Zurich, Switzerland. Raghvendra.Dubey@usz.ch
Trends in Endocrinology and Metabolism: TEM
|September 8, 2009
Summary
2-Methoxyestradiol (2-ME), an estradiol metabolite, shows promise for cardiovascular diseases by inhibiting cell replication and angiogenesis. Further research is needed to confirm its in vivo effectiveness in modulating vascular processes.
Area of Science:
- Endocrinology
- Vascular Biology
- Pharmacology
Background:
- 2-Methoxyestradiol (2-ME) is a metabolite of 17beta-estradiol.
- 2-ME exhibits in vitro growth-inhibitory effects on smooth muscle and endothelial cells.
- 2-ME possesses potential antiangiogenic properties.
Purpose of the Study:
- To explore the therapeutic potential of 2-ME for cardiovascular diseases.
- To review mechanisms of 2-ME in regulating vascular activity and angiogenesis.
- To discuss the in vivo efficacy of 2-ME.
Main Methods:
- In vitro studies on cell replication.
- Analysis of antiangiogenic properties.
- Review of recent developments in vascular biology.
Main Results:
- 2-ME inhibits key processes of cell replication in vitro.
- 2-ME demonstrates potent growth-inhibitory effects on proliferating cells.
- The in vivo effectiveness of 2-ME remains under investigation.
Conclusions:
- 2-ME's low cytotoxicity and estrogenicity suggest therapeutic potential for cardiovascular diseases.
- Understanding 2-ME's mechanisms in vivo is crucial.
- Further research is warranted to validate 2-ME as a cardiovascular therapeutic.
Related Concept Videos
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:26Secondary Messengers in Hormone Action
Water-soluble hormones cannot cross the plasma membrane, so they rely on protein receptors that span the membrane to trigger intracellular signaling pathways. These pathways then activate second messengers inside the cell, including cAMP or calcium ions.
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
01:20Vascular Resistance
Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...